唑来膦酸联合替勃龙治疗绝经后妇女骨质疏松的临床疗效

Clinical Effect of Zoledronic Acid Combined with Tebron in the Treatment of Osteoporosis in Postmenopausal Women

目的:探讨在绝经后妇女骨质疏松中应用唑来膦酸联合替勃龙治疗的临床疗效。方法:选取2018年9月至2020年1月在东莞市中堂医院就诊的女性骨质疏松患者120例,随机数字表法分为对照组、替勃龙治疗组(A组)、唑来膦酸治疗组(B组)和唑来膦酸联合替勃龙治疗组(C组),每组30例,观察比较四组患者治疗前后骨代谢功能变化和治疗期间不良反应发生情况。结果:治疗前,四组患者的骨钙素、血清Ⅰ型前胶原肽(CTX)、骨碱性磷酸酶(BALP)、疼痛评分比较,差异无统计学意义(P>0.05);治疗后,四组患者以上相关指标均得到显著改善,且C组改善更明显,差异具有统计学意义(P<0.05)。A组、C组患者的不良反应发生率高于对照组,差异具有统计学意义(P<0.05);C组患者的不良反应发生率高于A组和B组,差异具有统计学意义(P<0.05)。B组和C组脆性骨折发生率明显低于对照组,差异具有统计学意义(P<0.05)。A、B、C三组脆性骨折发生率比较,差异无统计学意义(P>0.05)。结论:予以绝经后妇女骨质疏松唑来膦酸联合替勃龙治疗临床疗效显著,可有效改善患者的骨代谢功能。

Objective To investigate the clinical efficacy of using zoledronic acid combined with tebrurone in osteoporosis in postmenopausal women.Methods 120 women patients with osteoporosis were treated in Dongguan Zhongtang Hospital from September 2018 to January 2020.The randomized digital table was divided into control group,tebron treatment group(A group),zoledronic acid treatment group(B).30 patients each observed and compared bone metabolic function changes and adverse reactions during treatment.Results Before treatment,osteocalin,serotype precollagen peptide(CTX),bone alkaline phosphatase(BALP)and pain score comparison(P>0.05).After treatment,they were significantly improved(P<0.05).Higher rates of adverse reactions in A and C than in controls were statistically significant(P<0.05);higher than in A and B,and statistically significant(P<0.05).The incidence of brittle fractures was significantly lower than in control groups,and the difference was statistically significant(P<0.05).The incidence of brittle fractures was significantly lower in the B and C than in the controls(P<0.05);and the incidence of brittle fracture(P>0.05).Conclusion The treatment of osteoporosis zoledronic acid with tebolone can improve the bone metabolic function.